地西他滨联合化学治疗对中高危慢性粒单核细胞白血病的疗效分析(1)
【摘要】 目的 探討地西他滨联合化学治疗对中高危慢性粒单核细胞白血病(CMML)的疗效。方法 分析接受地西他滨联合化学治疗的21例中高危CMML患者临床资料，总结疗效。结果 21例患者中男15例、女6例，年龄48(21 ～ 72)岁，CMML特异性预后评估系统(CPSS)危险评分均为中高危。接受地西他滨联合化学治疗第1疗程后16例(76.2%)患者获得完全缓解，1例(4.8%)患者获得骨髓完全缓解，第1疗程总反应率为81.0%，无治疗相关死亡患者。21例随访时间18(2 ～ 55)个月，中位生存时间17.6个月。11例年龄43(21 ～ 53)岁的患者在接受中位疗程为3个疗程的联合方案治疗后进行了异基因造血干细胞移植，随访时间7 ～ 55个月，中位生存时间18个月，移植后复发率9.1%(1/11)。结论 地西他滨联合化学治疗可使中高危CMML患者获得较高的完全缓解率，且患者耐受性良好。
【关键词】 慢性粒单核细胞白血病;中高危;地西他滨;缓解率;化学治疗
, http://www.100md.com Clinical efficacy of decitabine combined with chemotherapy in treatment of intermediate-and high-risk chronic myelomonocytic leukemia Liu Fengqi， Liang Ziyang， Wang Hehua， Su Chang， Liu Junru， Huang Beihui， Zou Waiyi， Zheng Dong， Xu Duorong， Zhou Zhenhai， Tong Xiuzhen， Li Juan. Department of Hematology， the First Affiliated Hospital of Sun Yat-sen University， Guangzhou 510080，China
Corresponding author， Tong Xiuzhen， E-mail：tongxz05@ 163. com
, 百拇医药
【Abstract】 Objective To evaluate the clinical efficacy and safety of decitabine combined with chemotherapy in the treatment of intermediate-and high-risk chronic myelomonocytic leukemia (CMML). Methods Clinical data of 21 patients with intermediate-and high-risk CMML who received decitabine combined chemotherapy were retrospectively analyzed. Clinical efficacy and safety were assessed. Results
Among 21 patients， 15 cases were male and 6 female， aged 48 years on average (range， 21-72 years). All patients were classified as intermediate-and high-risk CMML according to the CMML-specific prognostic scoring system (CPSS). Sixteen patients (76.2%) achieved complete remission (CR) and 1 (4.8%) had marrow CR (mCR) after one course of decitabine combined with chemotherapy， with an overall response rate (ORR) of 81.0%. No treatment-related death was observed. The average follow-up duration was 18 months (range， 2 to 55 months). The median overall survival was 17.6 months. Eleven patients with a median age of 43 years (range， 21-53 years) received allogeneic hematopoietic stem cell transplantation (allo-HSCT) after three courses of joint regimen. They were followed up for 7-55 months. The median overall survival was 18 months. The recurrence rate was 9.1% after allo-HSCT (1/11). Conclusions Decitabine combined with chemotherapy yields relatively high CR rate and excellent tolerance for patients with intermediate-and high-risk CMML.
【Key words】 Chronic myelomonocytic leukemia;Intermediate-and high-risk;Decitabine;, 百拇医药(刘凤琪 梁子杨 王荷花 苏畅 刘俊茹 黄蓓晖 邹外一 郑冬 许多荣 周振海 童)
【关键词】 慢性粒单核细胞白血病;中高危;地西他滨;缓解率;化学治疗
, http://www.100md.com Clinical efficacy of decitabine combined with chemotherapy in treatment of intermediate-and high-risk chronic myelomonocytic leukemia Liu Fengqi， Liang Ziyang， Wang Hehua， Su Chang， Liu Junru， Huang Beihui， Zou Waiyi， Zheng Dong， Xu Duorong， Zhou Zhenhai， Tong Xiuzhen， Li Juan. Department of Hematology， the First Affiliated Hospital of Sun Yat-sen University， Guangzhou 510080，China
Corresponding author， Tong Xiuzhen， E-mail：tongxz05@ 163. com
, 百拇医药
【Abstract】 Objective To evaluate the clinical efficacy and safety of decitabine combined with chemotherapy in the treatment of intermediate-and high-risk chronic myelomonocytic leukemia (CMML). Methods Clinical data of 21 patients with intermediate-and high-risk CMML who received decitabine combined chemotherapy were retrospectively analyzed. Clinical efficacy and safety were assessed. Results
Among 21 patients， 15 cases were male and 6 female， aged 48 years on average (range， 21-72 years). All patients were classified as intermediate-and high-risk CMML according to the CMML-specific prognostic scoring system (CPSS). Sixteen patients (76.2%) achieved complete remission (CR) and 1 (4.8%) had marrow CR (mCR) after one course of decitabine combined with chemotherapy， with an overall response rate (ORR) of 81.0%. No treatment-related death was observed. The average follow-up duration was 18 months (range， 2 to 55 months). The median overall survival was 17.6 months. Eleven patients with a median age of 43 years (range， 21-53 years) received allogeneic hematopoietic stem cell transplantation (allo-HSCT) after three courses of joint regimen. They were followed up for 7-55 months. The median overall survival was 18 months. The recurrence rate was 9.1% after allo-HSCT (1/11). Conclusions Decitabine combined with chemotherapy yields relatively high CR rate and excellent tolerance for patients with intermediate-and high-risk CMML.
【Key words】 Chronic myelomonocytic leukemia;Intermediate-and high-risk;Decitabine;, 百拇医药(刘凤琪 梁子杨 王荷花 苏畅 刘俊茹 黄蓓晖 邹外一 郑冬 许多荣 周振海 童)
参见：首页 > 医疗版 > 疾病专题 > 血液内科 > 白血病